In addition, eu-DKA due to SGLT-2 inhibitor use may be accompanied by electrolyte disturbances, such as hypovolemic hypernatremia and hypokalemia, necessitating an appropriate fluid therapy and close monitoring. This evidence concerns the gene SLC5A2 and Hypokalemia.